Press release
Datamonitor: Pricing and Reimbursement in the United Arab Emirates on reports-research.com
Research and analysis highlights
Reforms undertaken in the UAE will increase healthcare access to all expatriates, and improve the quality of care provided in both the public and private sector. With patients placed at the centre of the reforms, the focus will be on preventive care rather than curative treatment since the UAE is burdened by chronic diseases such as diabetes.
Greater involvement of private insurers through compulsory employer financed health insurance will mature the health insurance industry. Datamonitor believes that insurers will emerge as the dominant influencer of the healthcare industry as relationships between providers, payers and Pharma change as a result of the reforms.
With the implementation of tighter pricing and reimbursement controls, the pharmaceutical market is expected to evolve, driven by initiatives to increase the use of generics and stricter prescribing practices. However, consumer attitudes towards generic drugs will need to be changed for such cost-containment measures to be fully realized.
Scope of this research
- Overview of the healthcare reforms undertaken in Abu Dhabi and Dubai in order to contain costs
- Strategic analysis of the changes in interaction between payers, providers of healthcare and pharmaceutical firms
- Review of potential pricing and reimbursement strategies to be adopted by insurers
- Commercial implications of the reforms on all businesses in the UAE
Datamonitor: Pricing and Reimbursement in The United Arab Emirates:
http://www.markt-studie.de/studien/pricing-reimbursement-united-arab-emirates-p-61788.html
Datamonitor: More market data and market reports:
http://www.markt-studie.de/studien/datamonitor-m-29.html
markt-studie.de, founded in 2002 has emerged as a leading online portal for market surveys and market research in German speaking areas. Four years later the English language portal reports-research.com was introduced due to the extraordinary success of the portal. Again one year later estudio-mercado.es - the Spanish spoken portal - was founded. The objective of the three portals is to competently and efficiently support consultants and decision makers in management, sales and marketing in the search for worldwide market research. Prospective buyers can look into more than 60,000 market surveys from more than 200 international publishers, current market data for more than 6,000 branches worldwide, 10,000 company profiles as well as a free-of-charge research and recommendation service for individual market research.
reports-research.com
c/o dynamic technologies GmbH
Siegburger Str. 233
50679 Köln
Germany
Manuel Bravo Sanchez (CEO)
info@reports-research.com
or
Tel ++49 (0)221 690 688 55
Fax ++49 (0)221 690 688 56
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Datamonitor: Pricing and Reimbursement in the United Arab Emirates on reports-research.com here
News-ID: 90442 • Views: …
More Releases from dynamic technologies Gmbh, Köln, Germany
Canadean: New Zealand - The Future of Foodservice to 2016
The New Zealand foodservice market recorded a CAGR of 1.43% during the review period. Per capita sales increased at a review period CAGR of 0.38%. In 2011, the profit sector contributed 92.1% to the country’s total foodservice sales and posted a per capital sales CAGR of 0.33%. Growth in the profit sector is attributable to the growth in the restaurant channel which grew by a CAGR of 1.56%. In…
yStats.com: South Korea B2C E-Commerce Report 2011 published on reports-research …
The latest South Korea B2C E-Commerce Report 2011, compiled by Hamburg-based market research firm yStats.com features important B2C E-Commerce facts and figures on South Korea. In addition to revenue figures, market shares and customers, the report also covers general online use, the latest trends and major competitors.
In 2010, the number of internet users in South Korea rose to more than 35 million. Growth rates were very low in the last…
yStats.com: Turkey Top 100 E-Commerce Players 2011 published on reports-research …
The latest and highly informative Turkey Top 100 E-Commerce Players 2011 ranking, compiled by the Hamburg-based market research firm yStats com, presents the 100 most successful players on the Turkish E-Commerce market. Turkey’s top 100 E-Commerce players have been ranked based on local unique visitor numbers from September 2011.
The yStats com ranking highlights important details about competitors in the Turkish E-Commerce sector, shareholders, business models, product ranges, local and…
GlobalData: Wind Power - Global Market Size, Turbine Market Share, Installation …
Wind Power - Global Market Size, Turbine Market Share, Installation Prices, Regulations and Investment Analysis to 2020 is the latest report from GlobalData, the industry analysis specialists that offer comprehensive information and understanding of the Global Wind Power market.
The research provides an understanding of the technology, key drivers and challenges in the global wind power market. It also provides historical and forecast data to 2020 for installed capacity and power…
More Releases for Datamonitor
Datamonitor: MannKind - FDA's second rejection casts doubt on Afrezza's future
The FDA has requested further Phase III trials of MannKind's inhaled insulin Afrezza with its next generation Dreamboat inhaler before it can be approved. Should it eventually receive approval, Afrezza is likely to attract only a niche patient population, and Datamonitor forecasts that it will garner low sales compared to its competitors, due to safety fears and limited demand for inhaled insulin.
MannKind has announced a further delay for its inhaled…
Datamonitor: Australia - election outcome offers renewed hope for pharmaceutical …
Earlier in 2010, Medicines Australia negotiated a Memorandum of Understanding with the Labor government which was meant to provide stability for Australia's pharmaceutical industry. However, the election and subsequent hung parliament delayed its implementation. Now, with the Labor Party once more seated in power, Datamonitor expects the government to move forward with the existing agreement.
More than two weeks after the Australian election resulted in a hung parliament, Julia Gillard's Labor…
Datamonitor: Greece - pharmaceutical companies take a stand over pricing
Following the publication of a new pricing bulletin which aims to cut healthcare costs in Greece, a significant proportion of pharmaceutical companies currently operating in the country have challenged the new prices. While there are many ways in which companies can beat the new pricing laws, the regulations may prove harmful to pharmaceutical company sales in Greece and, indeed, across Europe.
The battle continues to rage between pharmaceutical companies and the…
Datamonitor: ATS 2010 - developments in IPF and cystic fibrosis
The FDA's recent refusal of Esbriet and the publication of new guidelines for the treatment of idiopathic pulmonary fibrosis drove considerable interest in this disease at the 2010 meeting of the American Thoracic Society. Furthermore, the approval of the first new inhaled antibiotic for cystic fibrosis in over a decade brought renewed focus on this rare but extremely debilitating disease.
Idiopathic pulmonary fibrosis (IPF) is an often fatal form of interstitial…
Datamonitor: Commercial Insight - Antihormonal Cancer Therapies on reports-resea …
Antihormonal cancer therapies are a class of drugs used predominantly in the treatment of breast cancer and prostate cancer. The high incidence of these tumor types translates into a significant commercial potential for drug developers. Collectively, the antihormonal therapy cancer brands generated sales of about $6.9 billion in the seven major pharmaceutical markets in 2008.
Research and analysis highlights
The antihormonals market was worth $6.9 billion in 2008 across the seven major…
Datamonitor: Commercial Insight - Cytotoxic Therapies on reports-research.com
Despite the advent of molecular targeted therapies, cytotoxic chemotherapy remains the cornerstone of cancer treatment and is used across nearly the entire spectrum of tumor types. A number of cytotoxic drugs are on the market, however only a few currently dominate in terms of revenues, with Taxotere (docetaxel; Sanofi-Aventis), Eloxatin (oxaliplatin; Sanofi-Aventis) and Gemzar (gemcitabine; Eli Lilly) the three leading cytotoxics in terms of sales in 2008, with 7MM annual…
